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Some breast cancers will regress following endocrine 
manipulation and are considered to be hormone dependent. 
It has been demonstrated that mammary tumors containing 
estrogen receptors are likely to exhibit hormone depen-
dency. Additional research has revealed the prese~ce of 
proteins whose synthesis is promoted by estrogen. Pro-
gesterone receptor is one such molecule, and its measure-
ment has been used as a predictor of response to endocrine 
therapy. Another protein whtch has been investigated as a 
possible indicator of hormone dependency is glucose-6-
phosphate dehydrogenase (G6PD), an essential enzyme in 
the hexose monophosphate shunt of glucose metabolism. 
In this investigation mammary cancer was induced in 
rats with the carcinogen 7, 12-dimethylbenz(a)anthracene 
CDMBA) . Mammary lesions which developed were biopsied and 
assayed for G6PD activity by means of spectrophotometry. 
Bilateral ovariectomies were performed on these rats at 
iii 
this time. Tumors which regressed following ovariectomy were 
classified as hormone dependent, while those which continued 
to grow were considered hormone independent, or autonomous. 
At the end of a 3-18 week period, the animals were sacri-
ficed, and second G6PD assays were conducted on the tumors. 
G6PD activity in hormone-dependent tumors was sig-
nificantly higher than the activity of hormone-independent 
tumors prior to ovariectomy (p < .001). After surgery, 
G6PD activity in the hormone-dependent group declined con-
siderably and was not significantly different from that of 
the autonomous group. Correlation between enzyme activity 
and percentage of tumor regression within the hormone-de-
pendent group was not significant. 
Some regressing tumors showed signs of regrowth during 
the period of observation. This small group of neoplasms 
demonstrated G6PD activity levels similar to those of the 
non-recurring hormone-dependent tumors both before and after 
ovariectomy. A significant correlation between enzyme ac-
tivity and length of remission could not be demonstrated. 
Results of this study support the association of high 
G6PD activity with hormone dependency in mammary cancer. 
Further research is necessary to establish reliable stan-
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Hormone dependency in breast cancer has been studied 
for many decades; however, the relationships between the 
various hormones and neoplasia remain incompletely under-
stood, Endocrine ablation experiments have yielded sig-
nificant clues. 
1 
Toward the end of the last century, dramatic re-
mission of recurrent breast cancer following bilateral 
ovariectomy was reported (1). Since the source of ova-
rian steroids was removed by this procedure, these cancers 
were termed "hormone dependent." Many years later, simi-
lar results were achieved among post-menopausal women 
through bilateral adrenalectomy. It was believed that 
regression occurred as a result of the elimination of 
adrenal cortical androgens which were aromatized to estro-
9ens by peripheral tissue, as well as by the tumor itself 
(2, 3). Another operation which met with some success was 
hypophysectomy. This surgical procedure resulted in the 
removal of tropic hormones which stimulate steroid syn-
thesis and also of pituitary prolactin, a hormone impli-
cated in breast cancer development. 
In addition to these surgical treatments, chemical 
hormonal ablations have been introduced as therapy for 
hormone-dependent cancers. Anti-estrogens employed have 
included clomiphene, nafoxidine and tamoxifen (4). Med-
ical adrenalectomy has been accomplished by the admini-
stration of aminoglutethimide, which blocks the formation 
of glucocorticoids (5) and, additionally, inhibits the 
activity of aromatase (6). 
Cancer remission has also been induced, primarily in 
post-menopausal women, by pharmacological doses of estro-
gen (or estrogen agonists, such as diethylstilbestrol) .. 
The reason for this paradoxical effect is unclear, but 
some have proposed that the large amounts of estrogen in-
hibit the activity of prolactin (7, 8). 
Unfortunately, endocrine manipulations produce ob-
jective remissions in only about 30% of advanced breast 
cancers. Results of combined studies employing various 
endocrine therapies are summarized in Table 1. Evidently, 
not all breast cancers are hormone dependent. Those which 
are tend to confer a survival advantage upon their hosts, 
since hormone-dependent tumors are generally less aggres-
sive than autonomous tumors. 
2 
Researchers have developed animal models to study the 
cell biology of hormone dependency in cancer. Nucleophilic 
aromatic hydrocarbons have long been implicated in carcino-
genesis. These substances, or their metabolites, are usu-
ally electron donors and readily form associations with nuc-
leophiles, altering the cellular DNA (9). One hydrocarbon 
Table 1. Objective Response Rates 
to Various Forms of Endocrine Therapy 
Taken from Henderson and Canellos (4) 
Therapy No. of Response Range 
3 
of 
Patients Rate (%) Response Rate 
Hormones 
Estrogens 1683 26 15-38 
Androgens 2250 21 10-38 
Progestins 508 25 9-43 
Corticosteroids 589 23 0-43 
Ablation 
Oophorectomy 1674 33 21-41 
Adrenalectomy 3739 32 23-46 
Hypophysectomy 1174 36 22-58 
Antiestrogens 
Tamoxifen 504 35 22-49 
Nafoxidine 283 31 28-38 
Clomiphene 167 28 16-39 
Medical Adrenalectomy 
Aminoglutethimide 280 31 25-50 
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used extensively for the induction of rat mammary tumors 
is 7, 12-dimethylbenz(a)anthracene (DMBA). Mammary cancer 
can be induced in rats by a single feeding of DMBA (10), 
and the tumors produced are usually hormone dependent (11). 
It has been discovered that DMBA, when administered intra-
gastrically, accumulates in the ovaries, adrenals and adi-
pose tissue (12), which may reflect the tendency of the 
induced mammary tumors to be hormone dependent. 
Steroid Action Mechanism 
During the 1960's the mechanisms by which steroid 
hormones act on their target cells became better under-
stood with the discovery of intracellular receptor pro-
teins (13). A current model for steroid action is il-
lustrated in Figure 1. 
The secreted hormone, bound to a steroid binding 
globulin, is systemically transported to the target cell. 
Here the steroid molecule is dissociated from its binding 
globulin and, being lipophilic, readily penetrates the 
cell membrane. In the cytosol the steroid is bound to 
a receptor protein. The steroid-receptor complex is trans-
located to the cell nucleus where it becomes attached to 
the chromatin, activating the DNA promoter region which 
stimulates the transcription of RNA. The RNA transcript 
is processed, and rnRNA is transported to the cytoplasm 
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Figure 1. Model of Steroid Action Mechanism 
The steroid is designated as Sand the receptor (a dimer) as RA and RB. 
Taken from O'Malley (14) 
lJl 
translation of a new protein. This new protein alters 
the functioning of the target cell (14). 
Although the location of estrogen receptor in the 
cytosol has recently been questioned (15, 16), the model 
described above is generally accepted as an explanation 
of the steroid mechanism. The presence of receptor in a 
target cell is considered to be an indication of normal 
endocrine responsiveness. Loss of receptor during malig-
nant transformation results in ~he abolition of endocrine 
control and elimination of hormone dependency (17). 
Breast Cancer Evolution 
6 
The presence of a spectrum of hormone dependency among 
breast tumors has been described by Manni (18). Among the 
prevailing theories of mammary cancer evolution is the de-
velopment and selection of dedifferentiated, highly pro-
liferative, autonomous clones from an initially hormone-
dependent cell line (19). This model is supported by the 
research of Kim and Depowski (.20), who, using transplantable 
rat tumor, reported the progression from hormone dependency 
to autonomy accompanied by the emergence of distinct clones 
with different hormonal responsiveness. Recent receptor 
studies (21) lend further support to this concept. 
An alternative model has been proposed by Selby et al. 
(22), who have suggested the existence of undifferentiated 
tumor stem cells, some of which give rise to differenti-
ated, less proliferative, hormone-responsive progeny. The 
successful secondary hormonal therapy in patients whose 
cancer has relapsed following a response to previous en-
docrine manipulation ban be attributed to this stern cell 
model, and chemotherapy sequential to hormone treatment is 
proposed as a means of eliminating the remaining stern cell 
population. 
Hormonal Influences and Interactions 
7 
Animal models and in vitro studies of human cell lines 
have furnished clear evidence of hormonal influences on the 
development and regression of mammary carcinoma. Depriva-
tion of sex hormones in the rat has produced tumor regression 
marked by a sharp increase in the production of prostaglandin 
E2 and of cyclic AMP (23). A high molecular weight protein 
associated with tumor regression has been found to be phos-
phorylated by a cAMP-dependent protein kinase (24). 
It is generally recognized that estrogen promotes cell 
proliferation in both normal and malignant mammary tissue. 
Some research has furnished evidence that this stimulatory 
activity may be a negative effect resulting from the neut-
ralization of a serum-borne growth inhibitor (25). 
There has been some disagreement concerning the role 
of estrogen in tumor promotion. Some studies of rat tumors 
have suggested a secondary function of stimulating the 
release of prolactin by the pituitary (26). Both estro-
gen and prolactin have been demonstrated to counteract 
inhibitory effects of underfeeding on rat tumor growth 
(27), and both hormones have been regarded as essential 
for the development and growth of these tumors (28). 
8 
The receptor for prolactin in rat tumors was first 
described by Costlow et al. in 1974 (29). Hypophysecto-
mized animals undergo tumor regression which is not counter-
acted by estrogen administration (30). Anti-prolactin 
treatment has resulted in ~oth suppression of tumor for-
mation (31, 32) and in regression of induced rat mammary 
tumors (33). However, Leung et al. have reported that 
tumors regressing following ovariectomy or adrenalectomy 
were not stimulated by prolactin when administration was 
delayed (34). A secondary role for prolactin has been 
proposed, since this hormone has been shown to increase 
the concentration of estrogen receptor (35). 
Linkage of prolactin to human mammary cancer has been 
more equivocal. Anti-prolactin therapy rarely results in 
objective remissions, and some patients maintain high levels 
of serum prolactin despite tumor regression following pitu-
itary stalk section (17). 
,The presence of prolactin receptors in human breast 
tumors was established fairly recently (36). Shortly 
thereafter, Malarkey et al. reported in vitro cell pro-
liferation following prolactin administration in a cell 
line derived from a breast cancer patient (37). It has 
been suggested that selection mechanisms may operate to 
determine whether a particular tumor population responds 
to prolactin, estrogen or other hormones (38). 
Supportive roles in mammary cancer biology have been 
suggested for a variety of hormones. These include pro-
gesterone (39, 40), androgens (41), glucocorticoids (42), 
growth hormone (43), insulin (44) and melatonin (45). The 
possible interrelationships among all the various hormones 
mentioned above illustrate the complexity of breast cancer 
physiology. Hormone dependency apparently involves a con-
stellation of endocrine-mediated events. 
Steroid Receptor Evaluations 
9 
The discovery of steroid receptors was shortly fol-
lowed by the development of assay techniques to determine 
receptor concentrations and binding affinities in both 
nuclear and cytosolic fractions. Estrogen receptor could 
now be measured by employing radioligand competitive binding 
techniques and Scatchard analysis (46). 
When breast tumors were evaluated for estrogen re-
ceptor, it was found that_ some contained measurable levels 
10 
of receptor, while others did not. Of those patients with 
tumors positive for estrogen receptor, between 50 and 60% 
responded to endocrine therapy. (See Table 2.) 
With the refinement of receptor assay methods, it be-
came standard procedure to test primary breast cancers for 
the presence of estrogen receptor. Results of this assay 
could then be used at the time of recurrence to better as-
certain whether the patient was likely to benefit from hor-
monal manipulation. A patient whose tumor lacked estrogen 
receptor could be started on a regimen of chemotherapy. 
Since a considerable proportion of tumors possessing 
estrogen receptors nevertheless fail to· respond to hormone 
', 
therapy, investigators have inferred that this group of. 
ER+ tumors contains non-functioning receptors, i.e., the 
steroid mechanism is defective (48). There is evidence 
that this defect occurs at some point after estrogen-re-
ceptor binding has taken place (49, 50). 
In order to determine whether the estrogen mechanism 
is functioning, researchers could test for the presence of 
progesterone receptor, the synthesis of which is stimulated 
by estrogen. Horwitz et al. proposed it as a marker for 
hormone dependency (51). When tumors are measured for both 
estrogen receptor and progesterone receptor, those positive 
for both receptors exhibit a hormone responsiveness rate of 
Table 2. Clinical Correlations of Breast Cancer 
Remissions to Endocrine Therapy and 
Estrogen Receptor Content 
Taken from DeSombre and Jensen (47) 
Remissions/Cases 
Investigators ER+ (%) ER-
Blarney et al. 13/30 ( 43) 5/27 
Dao & Nemoto 64/119 (54) 4/56 
Degenshein et al. 27/45 ( 6 0) 1/15 
DeSombre & Jensen 39/62 ( 6 3) 4/108 
Lippman & Allegra 77/139 ( 55) 6/105 
Maass et al. 64/93 ( 6 9) 3/76 
Manni et al. 68/105 ( 6 5) 2/21 
McCarty et al. 32/58 (55) 7/40 
Nomura et al. 29/45 ( 6 4) 0/36 
Osborne et al. 69/145 ( 4 8) 5/53 
Paridaens et al. 14/31 ( 45) 0/18 
Rubens & Hayward 46/136 ( 3 4) 5/55 
Singhakowinta et al. 20/30 ( 6 7) 2/23 
Skinner et al. 17/30 ( 5 7) 5/44 
Wittliff 37/67 (55) 0/44 
Young et al. 46/83 (55) 6/22 
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Table 3. Clinical Correlations of Breast Cancer 
Remissions to Endocrine Therapy and 
Estrogen and Progestin Receptor Content 
Taken from DeSombre and Jensen (47) 
Remissions/Total Cases 
Investigators ER+PR+ ER+PR- ER-PR+ 
Allegra et al. 11/14 8/14 0/4 
Brooks et al. 4/6 2/7 
Dao & Nemoto 10/13 18/31 
Degen she in et al. 26/33 3/14 1/1 
King 10/11 3/15 0/2 
Manni et al. 15/24 3/5 
McCarty et al. 33/40 2/20 1/3 
Osborne et al. 16/20 14/45 
Skinner et al. 9/12 2/6 2/3 
Young et al. 20/29 3/14 1/2 
Totals 154/202 58/171 5/15 














75-80%. (See Table 3.) Progesterone receptor assay, con-
sequently, has become an additional diagnostic tool with 
which. to assess hormone dependency. Indeed, some investi-
gators regard th.e level of progesterone receptor as a more 
reliable indicator than estrogen receptor (52). One pro-
posed course of advanced breast cancer therapy based on 
positive estrogen and progesterone receptor findings is 
outlined in Table 4. 
Glucose-6-Phosphat~ Dehydrogenase 
Receptor assays involve difficult techniques and com-
plicated analyses (54). Many hospitals• are not equipped 
for these procedures ·and must send frozen· biopsies else-
where. Since temperature changes during and after surgery 
affect receptor stability (55, 56), assay results may be 
imprecise. Therefore, some researchers have sought to 
identify additional proteins with which to test the estro-
gen mechanism. 
Ringler and Hilf (57) demonstrated that estrogen pro-
motes the synthesis of the enzyme glucose-6-phosphate de-
hydrogenase in transplantable rat mammary tumor and that 
this increase is shortly followed by an increase in enzyme 
activity. Glucose-6-phosphate dehydrogenase (G6PD) is an 
enzyme involved in the hexose monophosphate (HMP) shunt of 
glucose metabolism. Figure 2 illustrates this particular 
14 
Table 4. Proposed Sequential Hormonal Therapy 
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In mammals the significance of the HMP shunt lies 
chiefly in some of the intermediate products formed. Par-
ticularly important are the pentoses, which are incorpor-
ated into nucleotides, and NADPH, a coenzyme essential for 
the synthesis of nucleic acids, fatty acids and steroids. 
The rate-limiting reaction (circumscribed in Figure 2) is 
catalyzed by G6PD. 
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High levels of G6PD activity are found in the ovary, 
liver and lactating mammary gland, as well as in adipose 
tissue (59). Hormone-dependent mammary tumors in mice ex-
hibit levels somewhere between those found in virgin and 
lactating mammary gland (60). The hormone-dependent human 
breast cancer cell line MCF-7 has demonstrated a higher 
level of activity than a benign tumor line (.61L 
Human breast cancer studies comparing estrogen receptor 
content with G6PD activity have resulted in conflicting re-
ports. Poulsen and Frederiksen (62) could find no relation-
ship between the two parameters. Hilf et al. (63) reported 
a lower level of enzyme activity in estrogen-receptor posi-
tive cancers than in those which were ER negative. However, 
opposite results were obtained by Daehnfeldt and Schulein 
(64) and by Duffy and Duffy (65). 
Some explanation of these apparent contradictions may 
have been supplied by the research of Messeri et al. (66). 
16 
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These studies seem to indicate the existence of two groups 
among the ER positive human cancers: those with high levels 
of G6PD activity and those whose enzyme activity is essen-
tially the same as that observed among ER negative cancers. 
These results suggest that those samples with high enzyme 
activity may represent hormone-dependent tumors, in which 
the estrogen mechanism is functioning, i.e., producing the 
appropriate protein. 
Association of high levels of G6PD activity with hor-
mone dependency has been demonstrated in experimental rodent 
mammary tumors (60). A significant decline in the enzyme ac-
tivity of hormone-dependent tumors following ovariectomy has 
been reported (67, 68). Research by Briand and Daehnfeldt 
(60) has indicated that G6PD activity levels in autonomous 
tumors do not increase upon administration of estrogen, a 
finding supportive of the steroid action model. 
In addition to its usefulness as a predictor of hormone 
dependency, G6PD activity (along with the activity of some 
other enzymes) has been proposed by Savlov et al. as a pre-
dictor of responsiveness to adjuvant chemotherapy (69). Pa-
tients with low levels of enzyme activity were shown to be 
more likely to experience recurrence within one year fol-
lowing chemotherapy, regardless of estrogen receptor status. 
While induced rat mammary cancers differ in some respects 
from human breast carcinoma (propensity to metastasize, for 
18 
example), the basic biology of hormone dependency is similar. 
This study will attempt to determine if G6PD activity is an 
accurate predictor of hormone dependency in DMBA-induced rat 
tumors. 
19 
MATERIALS AND METHODS 
Tumor Induction 
Immature female Sprague-Dawley rats were obtained 
from Harlan Industries, Indianapolis, IN. They were main-
tained in a temperature and light-controlled environment 
and supplied with water and Purina Rodent Chow (Ralston-
Purina Co., St. Louis, MO) ad libitum. 
At age 50 :I: 1 days, under light ether anesthesia, 
these animals received a single dose of 20 mg. 7, 12-di-
methylbenz(a)anthracene in 2 ml. of peanut oil emulsion 
by gastric intubation. Beginning six weeks after carcino-
gen administration, the rats were palpated weekly for 
tumors. The first tumors were detected two months fol-
lowing DMBA treatment. 
Surgery 
An animal was considered for surgery when at least 
one tumor exceeded 1 cm. in diameter. The rat was anes-
thetized with an intra-peritoneal injection of sodium 
pentobarbital (Butler Co., Columbus, OH) at a dose of 
4 mg. per 100 g. of body weight. All tumors were then 
measured with calipers. The number of tumors ranged 
from one to eight per animal, the average. rat possessing 
three. Dimensions measured were the longest diameter 
and the diameter perpendicular to this axis and parallel 
to the ventral surface. All tumors were mapped for fu-
ture identification. 
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Bilateral ovariectomy was performed. The largest 
tumor was then selected for biopsy. Skin and surrounding 
fatty tissue were removed. A large tumor sample ( > 1 g.) 
was weighed, frozen in acetone-dry ice, and s_tored at 
-20° C for future receptor assays. A smaller sample 
(about 100 mg.) of the same tumor was used for enzyme 
studies. 
Glucose-6-Phosphate Dehydrogenase Assay 
The small biopsy material was weighed and homogenized 
in physiological saline containing 6.6 x 10-4 M disodium 
EDTA, 0.04 ml. per mg. of tissue. Homogenization was ac-
complished by two minutes of mechanical pulverization with 
a 7 ml. glass homogenizer embedded in ice. The homogenate 
was then centrifuged at 4° for ten minutes at 20,000 g.· 
The supernatant was decanted and assayed for G6PD activity 
according to the procedure of Lohr and Waller (70) as fol-
lows: 
Three cuvettes were used for each sample: one refer-
ence and two experimental replicates. Into each cuvette 
was pipetted 2.8 ml. triethanolamine buffer consisting of 
0.9% triethanolamine hydrochloride in a 2% aqueous solution 
of disodium EDTA; adjusted to pH 7.5. This was followed 
by 0.1 ml. sample supernatant. The replicate cuvettes 
then received 0.05 ml. NADP (0.03 Min 1% sodium bicar-
bonate), while an equivalent volume of buffer was added 
to the reference cuvette. An incubation period of five 
minutes was allowed for equilibration. After this time 
had elapsed, 0.05 ml. glucose-6-phosphate (0.04 M) was 
added to all cuvettes. 
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Spectrophotometric measurement of G6PD activity is 
based on the increase in absorbance which follows the re-
duction of NADP to NADPH. Absorbance at 340 nm. was re-
corded for all cuvettes at one-minute.intervals during a 
ten-minute period, using an LKB Biochrom 4050 ultraspec-
trophotometer. Changes in absorbance of the reference 
cuvette (usually negligible) were subtracted from those 
of the experimental replicates. Enzyme activity was cal-
culated in terms of Wroblewski units by the formula: 
11 E340 / min. x 10 (dilution factor)= G6PD units/ml. --------
0.001 
Because of tumor heterogeneity, it was necessary to 
determine specific enzyme activity, and a protein assay 
was performed on the remaining homogenate. Bradford's 
method (71), based on the staining reaction of Coomassie 
Brilliant Blue (Bio-Rad, Richmond, CA), was employed. (This 
technique has certain advantages over the Lowry method 
for protein determination in that only one reagent is 
necessary, incubation time can be as short as five min-
utes, and only one wavelength is required for all spec-
trophotometric readings.) Bovine serum globulin (Sigma 
22 
Chemical Co., St.-Louis, MO) was used as standards. Speci-
fic enzyme activity was expressed as Wroblewski units per 
mg. protein. 
Follow-Up 
After surgery, all surviving animals were examined 
weekly, and their tumors were measured as described above. 
Since a considerable portion of tumor ·had been removed 
during biopsies, measurements taken one week following 
ovariectomy were used as a basis for assessing tumor re-
gression. Because some of the frozen biopsies were very 
large and extended along the length of the longer axis, 
measurement of this long diameter only was employed for 
these tumor comparisons. In the case of other biopsied 
and all non-biopsied tumors, the geometric mean of the 
two diameters was used in estimations of size. Hence, 
evaluation of tumor size is always linear. 
In order to distinguish clearly between regressing 
(hormone-dependent) and non-regressing (hormone-independent) 
tumors, certain criteria were established. A tumor could be 
23 
designated as hormone-dependent if its decrease in size 
between the first and third week post-operative was at 
least 15%, provided that thi·s decline was continuous·, 
Necrotic tumors were excluded from consideration. fur-
thermore, animals had to remain heal thy for thei1c tumors· 
to be included in this category. Tumors which continued 
to grow were considered non-responsive to hormonal ab.,-
lation and, therefore, classified as hormone-:independent. 
Animals were observed for three to eighteen weeks 
following surgery. Resumption of growth in previously• 
reqressing tumors was measured and recorded. 
At the end of this observation period, all animals 
were sacrificed by means of ether asphyxiation. Small 
samples (about 100 mg,} of the originally biopsied tumors 
(if they had not regressed completely} were assayed for-
G6PD activity as previously described, 
Data Evaluati·on 
All data obtained in this study were processed i·n 
conformance with accepted procedures for, one-way analysis 
of variance and statistical correlation (72) • The ONEWAY 
and SCATTERGRAM programs of the Statistical Package fo.r the 
Social Sciences ( SPSS} were employed respectively (_7 3 }_, 
24 
RESULTS 
Of a total of 56 biopsied tumors·which were observed 
for at least three weeks following surgery, 48 were cat-
egorized as either hormone dependent-or hormone indepen-
dent. The remainder did not fit into the classification 
scheme described earlier, i. e., some became necrotic, etc. 
As illustrated in Table 5, there is no significant dif-
ference in size between the hormone-dependent and autono-
mous tumors prior to ovariectomy. 
The basis for determination of hormo.ne dependency is 
tumor regression following ovariectomy. These data are 
expressed in Table 6 as size of tumor three weeks post-
surgery. The hormone-dependent group exhibited highly 
significant regression (p < .001), while the hormone-in-
dependent tumors continued to grow. 
Twenty-seven, or 56% of the 48 tumors were classi-
·fied as hormone dependent. This percentage is lower than 
that generally reported for DMBA-induced rat mammary can-
cer and may represent a biased sampling. Each tumor se-
lected for biopsy was the largest one growing in that 
particular animal. The geometric means of the diameters 
were, on the average, over 2 cm. A sampling consisting 
of large tumors is likely to contain a disproportionate 
25 
number of aggressive, autonomous neoplasms. Some of the 
hormone-dependent tumors resumed growth in subsequent weeks, 
suggesting a tendency to become autonomous. 
Table 5. Size of Biopsied Tumors at .Ovariectomy 
(Data represent mean± standard.error.) 
Group Size in Centimeters 
Hormone Dependent 2.3519 + 0.151 -
Hormone Independent 2.3771 + 0.145 
Total 2.3629 + 0.105 
Table 6. Size of Biopsied Tumors Three Weeks 
Post-Ovariectomy 
(N = 27) 
(N = 21) 
(N = 48) 
Group Size in Centimeters 
Hormone Dependent 1.3522 + 0.133 (N = 27) 
p < 
Hormone Independent 2.7943 + 0.193 (N = 21) 




Evaluation of the average initial size of all tumors, 
not only those which were biopsied and assayed for enzyme 
activity, is shown in Table 7. Of 118 tumors, 90, or 
about 76% proved to be hormone dependent, a ratio. more 
in line with that generally obtained for this type of tumor. 
It should be observed that there is a significant difference 
in pre-operative size between the two groups, the hormone-
dependent tumors tending to be smaller (P <.05). 
Table 7. Size of All Tumors at Ovariectomy 
Group Size in Centimeters 
Hormone Dependent 1. 7302 + 0.077 (N = 90) 
p < -05 
Hormone Independent 2.0743 + 0.150 (N = 28) 
Total 1.8119 + 0.069 (N = 118) -
Table 8. Size of All Tumors Three Weeks Post-OVariectomy 
Group Size in Centimeters 
Hormone Dependent 0.8270 + 0.076 (N = 90) 
p < .001 
Hormone Independent 2.5054 + 0.177 (N = 28) 
Total 1.2253 + 0.097 (N = 118) 
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Considering all tumors, the hormone-dependent cancers 
regressed in the three weeks following surgery, while the 
autonomous neoplasms grew larger. (See Table 8.) The 
sharp decline (over 50%) in average size for the hormone-
dependent group reflects the complete disappearance of 
many of the smaller cancers. About one third of all re-
gressing tumors showed evidence of recurrence in the suc-
ceeding period of observation. Of the 44 animals with 
multiple lesions, 15, or 34% possessed both hormone-de~ 
pendent and independent tumors. 
Table 9 indicates the specific G6PD activity at the 
time of surgery of those biopsied tumors for which such 
measurements could be obtained. The mean enzyme activity 
of the hormone-dependent tumors is about twice that of. 
the hormone-independent group, and this difference is highly 
significant (p < .001). 
Specific enzyme activity of these tumors at the time 
the animals were sacrificed is recorded in Table 10. The 
smaller number of hormone-dependent tumors at this later 
time is indicative of the total regression of some tumors 
and the resumption of growth by some others. The latter 
group could no longer be designated as hormone dependent. 
Enzyme activity of the hormone-dependent and independent 
tumors is not significantly different at the time of 
28 
sacrifice. It is interesting to note that the G6PD ac-
tivity of hormone-dependent tumors in the weeks following 
ovariectomy (Table 10) was almost identical to the activity 
of hormone-independent tumors at the time of surgery 
(Table 9). Figure 3 is a graphic illustration of G6PD 
activity of both groups of tumors before and after ovari-
ectomy. 
Table 9. G6PD Activity of Tumors at Ovariectomy_ 
Group Specific Enzyme Activity 
(G6PD Units/mg. Protein) 
Hormone Dependent 28.47 + 2.48 (N = 
Hormone Independent 14. 05 + 2.48 (N = 
Total 22.14 + 2.08 (N = 
Table 10. G6PD Activity of Tumors 3-18 Weeks 
Post-Ovariectomy 
Group Specific Enzyme 
(G6PD Uni ts/mg. 
Hormone Dependent 14.07 + 3.17 (N 
Hormone Independent 11. 96 + 1. 80 (N 
Total 12.80 + 1.64 (N 
23) 




















N = 23 
Hormone 
Independent 
N = 18 
Figure 3. Specific G6PD Activity 
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Post-Ovariectomy 




N = 12 
Hormone 
Independent 
N = 18 
Lines (I) delimit mean~ standard error. 
Data for the hormone-dependent tumors were analyzed 
to determine whether there was any correlation between 
G6PD activity and percentage of regression (adjusted by 
logarithmic transformation) between the first and third 
week post-operative. A positive correlation coefficient 
of 0.29 was obtained, which was not statistically sig-
nificant (.05 < p < .1). 
Of the original group of biopsied hormone-dependent 
tumors, five exhibited.definite indications. of regrowth 
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at some point following the third week post-operative as-
sessment. No differences in G6PD activity between the 
recurring and non-recurring tumors could be detected either 
at the time of'surgery (Table 11) or when the animals were 
sacrificed (Table 12). 
The recurring tumors were also analyzed to determine 
a possible relationship between .G6PD activity and time 
until resumption of growth. The five tumors seemed to 
demonstrate some positive correlation (r = 0.77) between 
enzyme activity and number of weeks in remission (range 
= 4-8 weeks). However, this correlation was not statis-
tically significant (. 05 < p < .1) in this small sample. 
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Table 11. G6PD Activity of Recurring and Non-Recurring 
Hormone-Dependent Tumors at Ovariectomy 
Group Specific Enzyme Activity 
(G6PD Units/mg. Protein) 
Recurring 29.00 + 3. 80 (N = 5) -
n.s. 
Non-Recurring 28.84 + 3.16 (N = 17) 
Total 28.88 + 2.56 (N = 22) 
Table 12. G6PD Activity of Recurring and Non-Recurring 
Hormone-Dependent Tumors Post-Ovariectomy 
Group Specific Enzyme Activity 
(G6PD Units/mg. Protein) 
Recurring 13.96 + 5.95 (N = 5) 
+ n.s. Non-Recurring 14.07 3.17 (N = 12) 
Total 14. 04 + 2.63 (N = 17) 
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DISCUSSION 
For the purpose of this study, a hormone-dependent 
cancer is considered to be one which must be supplied with 
estrogen in order to continue self-maintenance, while an 
autonomous tumor has no such requirement. If a tumor is 
dependent upon estrogen, it should regress after ovariec-
tomy, as was the case for 76% of the DMBA-induced rat mam-
mary tumors in this study (Table 8). 
That the level of G6PD activity was significantly 
higher (p < .001) among the hormone-dependent tumors than 
the hormone-independent ones prior to ovariectomy (Table 9) 
is an indication of an intact estrogen-receptor-protein 
synthesis system in the former group. These results are 
consistent with the findings of Ringler and Hilf (57) and 
Briand and Daehnfeldt (60), who used rodent models. Studies 
based on human cancers (62-66) offer conflicting results. 
However, these investigations compare G6PD activity with 
estrogen receptor which, by itself, is not a very accurate 
predictor of hormone dependency. Human breast cancers must 
be followed for several years to determine whether future 
recurrences are responsive to hormonal manipulation, and, 
to date, no sequential studies have been reported. 
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While hormone-dependent tumors in this study demon-
strate G6PD activity very significantly higher than do the 
hormone-independent tumors prior to endocrine ablation, the 
range of enzyme activity is a continuum, i.e., there is no 
sharp demarcation between h:Lgh and low levels of activity; 
If the median value is arbitrarily chosen as a dividing 
line between high and low levels of G6PD activity, about 
85% of the members of the higher group represent hormone-
dependent tumors. Perhaps repeated experiments could ul-
timately furnish a standard for establishing high and low 
levels of activity, relating them to hormone dependency. 
In this regard, standards for determining estrogen or pro-
gesterone receptor status are not quite uniform; lower 
limits for positive assessment have ranged from 3 to 20 
fmoles per mg. protein•. 
Upon further examination of the distribution of G6PD 
activity, it was observed that a considerable proportion 
of tumors (about 25%} in the lower half of the curve were 
hormone dependent. Unfortunately, increasing the relia-
bility of a test often decreases its sensitivity and in-
creases the likelihood of false-negative results. This 
effect can be observed in receptor evaluations. Although 
progesterone receptor assay determinations have improved 
the chances of predicting hormone dependency, as indicated 
in Table 3, over 30% of ER+ tumors lacking progesterone 
receptor respond to endocrine therapy. 
Possibly a multifactorial approach to predicting 
hormone dependency could be developed, and an index of 
predictor values established. Besides progesterone re-
ceptor and G6PD, enzymes, such as lactose synthetase (64) 
and a peroxidase (74), have been found to be synthesized 
by breast cancers in response to estrogen stimulation. 
Additional pr_oteins have ·recently been isolated and sug-
gested as markers for hormone dependency (75-78). 
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The importance of accurate prediction of hormone de-
pendency has increased with the development of a greater 
variety of aggressive treatments for primary breast cancer. 
Stage II primary carcinoma, where axillary lymph nodes show 
signs of metastasis, are usually presumed to have produced 
undetectable distal micrometastases as well, which can be 
controlled by chemotherapy (4). The newer forms of hor-
monal manipulation, such as anti-estrogens, are appropriate 
primary treatment for hormone-dependent cancer, and clinical 
trials of adjuvant hormonal therapy have been conducted. 
Among the findings of the National Surgical Adjuvant Breast 
and Bowel Project (NASBP) were lower survival rates for 
younger patients lacking estrogen and/or progesterone re-
ceptors when treated with tamoxifen and conventional chemo-
therapy than with chemotherapy alone (79). It was suggested 
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that tamoxifen may alter the metabolism of chemothera-
peutic agents by affecting the liver. If anti-estrogens 
do, in fact, interfere with other forms of therapy, proper 
evaluation of hormone dependency is obviously essential. 
A lack of significant correlation between enzyme ac-
tivity and percentage of regression between the first and 
third week post-operative may be due to the presence of 
other variables, such as original tumor size, and by the 
arbitrary time limit which was imposed. Some tumors which 
had regressed only moderately during the two-week period 
demonstrated greater diminution in succeeding weeks. 
Levels of G6PD activity for hormone-dependent cancers 
declined considerably following ovariectomy (Table 10), 
since the estrogen supply required for the synthesis of 
substantial amounts of this protein was drastically cur-
tailed. This decrease in enzyme activity is in agreement 
with the results obtained by Bodwin and Cho-Chung (67) and 
by Nicholson (68). 
In contrast, the low enzyme activity of the hormone-
independent tumors hardly exhibited any decrease after 
surgery. Figure 3 compares the G6PD activity of the two 
groups of tumors before and after ovariectomy. The non-
significant decline which did occur among tne autonomous 
group can possibly be attributed to small sub-populations 
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of cells within the tumor which retained hormone de-
pendency and which, consequently, were deprived of es-
trogen-stimulated G6PD synthesis by ovariectomy. Con-
versely, it is likely that within a hormone-dependent 
tumor there are subsets of cells which have lost their 
ability to respond to estrogen and which form the nucleus 
of a recurring autonomous tumor. 
Unfortunately, only five definite cases of growth 
resumption could be detected among the assayed, origi-
nally hormone-dependent tumors. Undoubtedly, had the 
animals been permitted to survive longer, more recur-
rences would have been observed. The recurring tumors 
expressed the same enzyme activity as the non-recurring 
ones both before and after ovariectomy (Tables 11 and 12). 
If a high level of G6PD activity is indicative of 
hormone dependency, the sharp decline in enzyme activity 
following surgery would seem to diminish the likelihood 
of a differentiated, hormone-dependent population regrowing 
in response to extra-ovarian sources of estrogen. Hence, 
these findings tend to refute the stem cell hypothesis of 
Selby et al. (22) and to lend support to the clonal se-
lection model (20) of a differentiated cell line progressing 
to autonomy. Since the number of assayed recurring tumors 
in this study is admittedly small, it would be premature to 
form any definite conclusions based on these results. 
A significant association between G6PD activity and 
length of remission could not be determined for the re-
current group. Perhaps a larger sample would have es-
tablished a more definite relationship. 
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This study would seem to furnish strong evidence in-
dicating a higher level of G6PD activity among hormone-
dependent rat mammary tumors than among autonomous neo-
plasms in response to ovarian'stimulati"on. Assay of tumors· 
for G6PD activity may therefore be a valuable tool in pre-
dicting hormone dependency. 
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SUMMARY 
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme 
whose synthesis in rat mammary tumors has been shown to be 
promoted by estrogen. Assays of G6PD activity can be em-
ployed to determine whether the steroid action mechanism 
is functioning, an indication of hormone dependency. 
In this study, hormone-dependent tumors yielded higher 
levels of G6PD activity than did autonomous neoplasms. Re-
moval of the primary estrogen source through ovariectomy 
resulted.in a substantial decline in enzyme activity in 
the former group but little change in the latter, lending 
support for the role of estrogen in the regulation of G6PD 
activity. 
A high level of G6PD activity can be regarded as a 
valid indicator of hormone dependency. It is suggested 
that a battery of assays encompassing this enzyme and other 
proteins whose synthesis is stimulated by estrogen could be 
established to improve predictions of hormone dependency 
and the management of breast cancer. 
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